Since Tfh may amplify B-cell responses and autoantibody production in lymphoid tissue and CD8+ Tfh cells are already increased in RA-risk individuals, targeting Tfh cells early could be tested as a new approach to prevent further disease progression during the earliest phases of RA. This evidence concerns the gene CD8A and rheumatoid arthritis.